Embla Medical HF Announces Strategic Investment in Streifeneder ortho.production GmbH

Reykjavik, Iceland and Copenhagen, Denmark, July 17, 2025 — Embla Medical HF (NASDAQ Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, has announced a significant strategic move by signing an agreement to invest in a majority share (51%) in Streifeneder ortho.production GmbH (“Streifeneder”). This investment marks a pivotal expansion in Embla Medical’s portfolio, aligning with its Growth'27 strategy.

Streifeneder ortho.production GmbH, a privately owned company, is part of Streifeneder KG (Group), a renowned supplier of orthopaedic solutions and operator of a large orthopaedic and prosthetic (O&P) clinic network in Germany. The company specializes in the development and supply of prosthetic and orthotic components, boasting sales of EUR 25 million in 2024 and employing approximately 100 people.

This acquisition is expected to bolster Embla Medical’s position in the orthopaedic mobility solutions market, enhancing its product offerings and expanding its reach in Europe. The strategic investment is anticipated to drive growth and innovation, leveraging Streifeneder’s expertise and established market presence.

Financial Overview of Embla Medical HF

As of July 15, 2025, Embla Medical HF’s close price stood at DKK 32.5, with a market capitalization of DKK 2,030,000,000. The company’s 52-week high was recorded at DKK 38 on December 4, 2024, while the 52-week low was DKK 25.005 on April 8, 2025. The price-to-earnings ratio is currently 30.27.

Recent Share Buyback Activity

In a related development, Embla Medical announced transactions under its share buyback program on July 14, 2025. During the period from July 7 to July 11, 2025, the company acquired 35,900 shares at an average price of DKK 33.16, as part of its ongoing efforts to optimize its capital structure.

Market Context

Embla Medical is listed on the OMX Nordic Exchange Copenhagen AS and operates in the Health Care Equipment & Supplies sector. The company is part of the broader health care industry, focusing on non-invasive orthopedic products, including artificial limbs, prosthetic components, and compression therapy products.

Short Interest in Danish Market

In the broader Danish market context, Embla Medical is among several companies with notable short interest. As of July 17, 2025, the company is shorted, reflecting investor sentiment and market dynamics.

This strategic investment in Streifeneder ortho.production GmbH underscores Embla Medical’s commitment to growth and innovation in the orthopaedic mobility solutions sector, positioning the company for continued success in the global market.